Literature DB >> 19608199

Association of socioeconomic status with the use of chronic therapies and healthcare utilization in children with cystic fibrosis.

Michael S Schechter1, Susanna A McColley, Stefanie Silva, Tmirah Haselkorn, Michael W Konstan, Jeffrey S Wagener.   

Abstract

OBJECTIVE: To determine whether previously reported socioeconomic status (SES)-related disparities in cystic fibrosis (CF) health outcomes vary by the indicator used (median household income by zip code [MIZ], maternal educational attainment [MEA], and state insurance coverage [MA]), and whether these disparities can be explained by differences in medical treatment. STUDY
DESIGN: A cross-sectional analysis of data on patients age <18 years from the Epidemiologic Study of Cystic Fibrosis (ESCF).
RESULTS: Disease severity showed a similar inverse correlation with all 3 SES measures. The number of stable clinic visits was unrelated to SES. Patients with MA had more sick outpatient visits and more courses of intravenous (IV) antibiotics for pulmonary exacerbations, and were more likely to be prescribed all chronic therapies. Low-MIZ patients had slightly fewer sick visits and more courses of IV antibiotics, and were more likely to receive oral nutrition supplements but less likely to receive macrolide prescriptions. Low-MEA patients were less likely to receive IV antibiotics at home, more likely to receive oral nutrition supplements, but less likely to receive macrolide prescriptions.
CONCLUSIONS: CF health outcomes are correlated with the SES spectrum, but these disparities are not explained by differential use of health services or prescription of chronic therapy. Future investigations should focus on the possible impact of environmental exposures and differences in disease self-management.

Entities:  

Mesh:

Year:  2009        PMID: 19608199      PMCID: PMC4161122          DOI: 10.1016/j.jpeds.2009.04.059

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  31 in total

1.  Bias and causal associations in observational research.

Authors:  David A Grimes; Kenneth F Schulz
Journal:  Lancet       Date:  2002-01-19       Impact factor: 79.321

2.  MSJAMA. The effects of socioeconomic status on health in rural and urban America.

Authors:  Susan J Blumenthal; Jessica Kagen
Journal:  JAMA       Date:  2002-01-02       Impact factor: 56.272

3.  Case-mix adjustment for evaluation of mortality in cystic fibrosis.

Authors:  Gerald T O'Connor; Hebe B Quinton; Richard Kahn; Priscilla Robichaud; Joanne Maddock; Thomas Lever; Mark Detzer; John G Brooks
Journal:  Pediatr Pulmonol       Date:  2002-02

4.  Spirometric reference values from a sample of the general U.S. population.

Authors:  J L Hankinson; J R Odencrantz; K B Fedan
Journal:  Am J Respir Crit Care Med       Date:  1999-01       Impact factor: 21.405

Review 5.  Ecologic studies in epidemiology: concepts, principles, and methods.

Authors:  H Morgenstern
Journal:  Annu Rev Public Health       Date:  1995       Impact factor: 21.981

6.  Patterns of medical practice in cystic fibrosis: part I. Evaluation and monitoring of health status of patients. Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis.

Authors:  M W Konstan; S M Butler; D V Schidlow; W J Morgan; J R Julius; C A Johnson
Journal:  Pediatr Pulmonol       Date:  1999-10

7.  Can patient self-management help explain the SES health gradient?

Authors:  Dana P Goldman; James P Smith
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-24       Impact factor: 11.205

8.  Interactions between secondhand smoke and genes that affect cystic fibrosis lung disease.

Authors:  J Michael Collaco; Lori Vanscoy; Lindsay Bremer; Kathryn McDougal; Scott M Blackman; Amanda Bowers; Kathleen Naughton; Jacky Jennings; Jonathan Ellen; Garry R Cutting
Journal:  JAMA       Date:  2008-01-30       Impact factor: 56.272

9.  Factors influencing outcomes in cystic fibrosis: a center-based analysis.

Authors:  Charles Johnson; Steven M Butler; Michael W Konstan; Wayne Morgan; Mary Ellen B Wohl
Journal:  Chest       Date:  2003-01       Impact factor: 9.410

10.  Simplifying children's Medicaid and SCHIP.

Authors:  Karl Kronebusch; Brian Elbel
Journal:  Health Aff (Millwood)       Date:  2004 May-Jun       Impact factor: 6.301

View more
  38 in total

1.  Area Deprivation as a Risk Factor for Methicillin-resistant Staphylococcus aureus Infection in Pediatric Cystic Fibrosis.

Authors:  Gabriela R Oates; William T Harris; Steven M Rowe; George M Solomon; Suranjana Dey; Aowen Zhu; Wynton C Hoover; Hector H Gutierrez
Journal:  Pediatr Infect Dis J       Date:  2019-11       Impact factor: 2.129

2.  Sociodemographic attributes and spina bifida outcomes.

Authors:  Michael S Schechter; Tiebin Liu; Minn Soe; Mark Swanson; Elisabeth Ward; Judy Thibadeau
Journal:  Pediatrics       Date:  2015-03-16       Impact factor: 7.124

3.  Socioeconomic Status, Smoke Exposure, and Health Outcomes in Young Children With Cystic Fibrosis.

Authors:  Thida Ong; Michael Schechter; Jing Yang; Limin Peng; Julia Emerson; Ronald L Gibson; Wayne Morgan; Margaret Rosenfeld
Journal:  Pediatrics       Date:  2017-01-16       Impact factor: 7.124

4.  Impact of Socioeconomic Position on Access to the U.S. Lung Transplant Waiting List in a Matched Cystic Fibrosis Cohort.

Authors:  Carli J Lehr; Aliza K Fink; Melissa Skeans; Albert Faro; Gabriela Fernandez; Elliott Dasenbrook; Maryam Valapour
Journal:  Ann Am Thorac Soc       Date:  2020-11

5.  Nationwide trends of hospitalizations for cystic fibrosis in the United States from 2003 to 2013.

Authors:  Abhinav Agrawal; Abhishek Agarwal; Dhruv Mehta; Rutuja R Sikachi; Doantrang Du; Janice Wang
Journal:  Intractable Rare Dis Res       Date:  2017-08

6.  Adherence to airway clearance therapy in pediatric cystic fibrosis: Socioeconomic factors and respiratory outcomes.

Authors:  Gabriela R Oates; Irena Stepanikova; Stephanie Gamble; Hector H Gutierrez; William T Harris
Journal:  Pediatr Pulmonol       Date:  2015-10-05

7.  Socioeconomic status and the likelihood of antibiotic treatment for signs and symptoms of pulmonary exacerbation in children with cystic fibrosis.

Authors:  Michael S Schechter; Susanna A McColley; Warren Regelmann; Stefanie J Millar; David J Pasta; Jeffrey S Wagener; Michael W Konstan; Wayne J Morgan
Journal:  J Pediatr       Date:  2011-06-25       Impact factor: 4.406

8.  Longitudinal association between medication adherence and lung health in people with cystic fibrosis.

Authors:  Michelle N Eakin; Andrew Bilderback; Michael P Boyle; Peter J Mogayzel; Kristin A Riekert
Journal:  J Cyst Fibros       Date:  2011-03-31       Impact factor: 5.482

9.  Early Childhood Risk Factors for Decreased FEV1 at Age Six to Seven Years in Young Children with Cystic Fibrosis.

Authors:  Don B Sanders; Julia Emerson; Clement L Ren; Michael S Schechter; Ronald L Gibson; Wayne Morgan; Margaret Rosenfeld
Journal:  Ann Am Thorac Soc       Date:  2015-08

10.  Disparities in access to lung transplantation for patients with cystic fibrosis by socioeconomic status.

Authors:  Bradley S Quon; Kevin Psoter; Nicole Mayer-Hamblett; Moira L Aitken; Christopher I Li; Christopher H Goss
Journal:  Am J Respir Crit Care Med       Date:  2012-09-13       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.